Vigil Neuroscience (VIGL) has made great progress in being able to advance its pipeline. It just reported interim results from its phase 2 IGNITE study, which used its drug iluzanebart [formerly ...
CHICAGO--(BUSINESS WIRE)--Syntellis Performance Solutions, the leading provider of enterprise performance management software, data and intelligence solutions, today announced the launch of Focus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback